Carvone / BAD Cancer Research Results

CRV, Carvone: Click to Expand ⟱
Features:

Carvone — Carvone is a chiral oxygenated monocyclic monoterpene ketone found mainly as enantiomeric forms in spearmint, caraway, dill, and related essential oils. It is best classified as a small-molecule natural product / volatile terpenoid flavor-fragrance compound, commonly abbreviated CRV. The biologically relevant forms are often reported as l-carvone, d-carvone, R-carvone, or S-carvone, but naming conventions are inconsistent across papers, so note the exact enantiomer stated by each source.

Primary mechanisms (ranked):

  1. Induction of cancer-cell apoptosis through p53, Bad, caspase-3 activation, PARP cleavage, and DNA-damage-associated stress signaling.
  2. Suppression of migration, adhesion, invasion, and metastatic behavior, especially through FAK-related signaling in breast cancer models.
  3. Context-dependent oxidative stress modulation, including ROS increase and DNA damage at cytotoxic in-vitro concentrations.
  4. Inhibition of proliferative survival pathways, including JAK/STAT3 in gastric cancer and p38 MAPK-related signaling in myeloma models.
  5. Cell-cycle disruption, reported as S-phase, G0/G1, or G2/M arrest depending on enantiomer, cancer model, and concentration.
  6. Possible chemopreventive activity in animal skin-carcinogenesis models, but not established as a clinically validated anticancer agent.

Bioavailability / PK relevance: Carvone is lipophilic and volatile, with oral, dermal, and inhalational exposure relevance depending on formulation. Human PK/metabolism data exist for ingestion-correlated and topical/percutaneous exposure contexts, but anticancer studies generally use concentrations that are not directly matched to validated systemic anticancer exposure. Essential-oil delivery introduces variability from enantiomer ratio, co-terpenes, oxidation products, and formulation.

In-vitro vs systemic exposure relevance: Common anticancer in-vitro effects occur at high micromolar to millimolar or microgram-per-millilitre ranges, and breast-cancer IC50 values around the millimolar range have been reported. These levels are likely above ordinary dietary flavor exposure and may exceed practical systemic exposure from food-like intake. Interpretation should therefore be concentration-constrained and formulation-dependent.

Clinical evidence status: Preclinical for cancer. Evidence includes cancer cell-line studies, animal chemoprevention/tumor models, and mechanistic studies, but no credible cancer RCTs of carvone as a therapeutic agent were identified. Human studies involving carvone-containing preparations exist for non-cancer indications or mixtures, but they should not be treated as direct anticancer evidence for isolated carvone.

Safety / regulatory status: Carvone is listed as a FEMA GRAS flavoring substance with CFR flavor-use reference, but this applies to intended flavor-use exposure, not therapeutic dosing. Major constraints include skin sensitization potential, enantiomer/formulation variability, volatile exposure, and uncertain safety at high supplemental or pharmacologic doses. Fragrance safety assessment data indicate no genotoxic concern under reviewed conditions, but l-carvone is considered a skin sensitizer.

Carvone Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Apoptosis execution ↑ p53, ↑ Bad, ↑ cleaved caspase-3, ↑ cleaved PARP Lower sensitivity reported in some normal-cell comparisons G Pro-apoptotic cytotoxicity Most central anticancer mechanism; strongest evidence is in vitro and concentration-dependent.
2 Migration adhesion invasion ↓ migration, ↓ adhesion, ↓ invasion, ↓ FAK activation Not well-defined G Anti-metastatic phenotype Mechanistically important for breast cancer models; therapeutic leverage is plausible but not clinically validated.
3 ROS and DNA damage stress ↑ ROS, ↑ DNA damage markers, ↑ apoptotic stress Context-dependent antioxidant or cytoprotective effects reported outside cancer R/G Stress-mediated apoptosis ROS appears pro-apoptotic in several cancer contexts; antioxidant effects in non-cancer models make this axis context-dependent.
4 JAK STAT3 survival signaling ↓ JAK/STAT3 signaling in gastric cancer models Not well-defined G Reduced survival signaling Promising but model-specific; should not be generalized across all tumor types without direct evidence.
5 p38 MAPK signaling ↓ p38 MAPK-related signaling in myeloma models Not well-defined G Growth and invasion suppression Reported in myeloma; secondary/contextual relative to apoptosis and motility effects.
6 Cell cycle control ↑ arrest at S, G0/G1, or G2/M depending on model Not well-defined G Reduced proliferation Direction of arrest is inconsistent across cancer systems and enantiomer reports; keep model-specific.
7 Mitochondrial apoptosis ↓ mitochondrial membrane potential reported in some models, ↑ caspase-linked apoptosis Context-dependent R/G Intrinsic apoptosis support Relevant when mitochondrial depolarization or ROS-mediated apoptosis is directly measured.
8 Angiogenesis tumor microenvironment ↓ angiogenesis stimulus in Ehrlich tumor context Not well-defined G Reduced tumor support phenotype Evidence is less mature than direct cancer-cell apoptosis and migration data.
9 NRF2 redox adaptation ↔ or uncertain Possible cytoprotective relevance in oxidative stress models G Unresolved redox adaptation
10 Clinical Translation Constraint High in-vitro concentrations may not map to achievable systemic exposure Skin sensitization and exposure-route constraints G Limits translational confidence Bioavailability, enantiomer identity, essential-oil composition, and flavor-use versus therapeutic-dose safety are the main constraints.

P: 0–30 min R: 30 min–3 hr G: >3 hr
BAD, BCL2 associated agonist of cell death: Click to Expand ⟱
Source:
Type:
BCL2 associated agonist of cell death (BAD) protein is a pro-apoptotic member of the Bcl-2 gene family.
Expression of the BAD is associated with the development and progression of cancer.
Scientific Papers found: Click to Expand⟱
6521- CRV,    L-carvone induces p53, caspase 3 mediated apoptosis and inhibits the migration of breast cancer cell lines
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, DNAdam↑, ROS↑, GSH↑, P53↑, BAD↑, cl‑Casp3↑, cl‑PARP↑, Apoptosis↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 2,   BAD↑, 1,   cl‑Casp3↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Migration ⓘ

TumCMig↓, 1,   TumCP↓, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: BAD, BCL2 associated agonist of cell death
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:411  Target#:426  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page